In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Repligen Corp (NASDAQ: RGEN) closed at $130.00 in the last session, down -1.59% from day before closing price of $132.10. In other words, the price has decreased by -$1.59 from its previous closing price. On the day, 0.75 million shares were traded. RGEN stock price reached its highest trading level at $131.51 during the session, while it also had its lowest trading level at $125.975.
Ratios:
We take a closer look at RGEN’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.64 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 50.17. For the most recent quarter (mrq), Quick Ratio is recorded 7.28 and its Current Ratio is at 8.41. In the meantime, Its Debt-to-Equity ratio is 0.35 whereas as Long-Term Debt/Eq ratio is at 0.34.
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Evercore ISI on March 18, 2025, initiated with a In-line rating and assigned the stock a target price of $155.
On February 10, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $200.
On December 17, 2024, Canaccord Genuity started tracking the stock assigning a Hold rating and target price of $165.Canaccord Genuity initiated its Hold rating on December 17, 2024, with a $165 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 17 ’25 when Hunt Anthony sold 26,756 shares for $152.51 per share. The transaction valued at 4,080,663 led to the insider holds 136,301 shares of the business.
Pax Margaret bought 250 shares of RGEN for $37,672 on Mar 17 ’25. The Director now owns 1,043 shares after completing the transaction at $150.69 per share. On Mar 17 ’25, another insider, Hunt Anthony, who serves as the Director of the company, bought 26,756 shares for $150.42 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGEN now has a Market Capitalization of 7421258240 and an Enterprise Value of 7228204032. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.51 while its Price-to-Book (P/B) ratio in mrq is 3.70. Its current Enterprise Value per Revenue stands at 11.393 whereas that against EBITDA is 67.364.
Stock Price History:
The Beta on a monthly basis for RGEN is 1.16, which has changed by -0.1727122 over the last 52 weeks, in comparison to a change of 0.0635103 over the same period for the S&P500. Over the past 52 weeks, RGEN has reached a high of $182.52, while it has fallen to a 52-week low of $102.96. The 50-Day Moving Average of the stock is -8.84%, while the 200-Day Moving Average is calculated to be -10.54%.
Shares Statistics:
According to the various share statistics, RGEN traded on average about 764.20K shares per day over the past 3-months and 1150180 shares per day over the past 10 days. A total of 56.09M shares are outstanding, with a floating share count of 53.02M. Insiders hold about 5.57% of the company’s shares, while institutions hold 100.80% stake in the company. Shares short for RGEN as of 1743379200 were 3541391 with a Short Ratio of 4.63, compared to 1740700800 on 3453504. Therefore, it implies a Short% of Shares Outstanding of 3541391 and a Short% of Float of 8.5.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
